Working… Menu

The Effect of Quercetin in Sarcoidosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00402623
Recruitment Status : Completed
First Posted : November 22, 2006
Last Update Posted : February 24, 2017
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by:
Maastricht University Medical Center

Brief Summary:

The exact cause of the chronic lung disease sarcoidosis is still unknown. Consequently, a complete efficacious treatment is still not available. Earlier studies indicate an important key role for oxidative stress, i.e. an imbalance between the production of and the protection against ROS, in the etiology of sarcoidosis. Antioxidants, needed for protection against ROS, are indeed lower in sarcoidosis. Therefore, antioxidant therapy to strengthen the reduced antioxidant defense might be efficacious in sarcoidosis treatment. Since ROS are also capable of initiating and mediating inflammation, antioxidant therapy might also mitigate the elevated inflammation that occurs in sarcoidosis. The flavonoid quercetin possesses both anti-oxidative and anti-inflammatory capacities and might therefore serve as a good candidate for antioxidant therapy in sarcoidosis.

Therefore, the aim of the present study is to determine the effect of quercetin supplementation in sarcoidosis patients on markers of both oxidative stress and inflammation.

Condition or disease Intervention/treatment Phase
Sarcoidosis Dietary Supplement: quercetin Other: placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Quercetin on the Increased Inflammatory and Decreased Antioxidant Status in Sarcoidosis
Study Start Date : January 2006
Actual Primary Completion Date : January 2006
Actual Study Completion Date : January 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Quercetin

Arm Intervention/treatment
Placebo Comparator: 1
Other: placebo
Active Comparator: 2
quercetin (food supplement)
Dietary Supplement: quercetin
1000 mg quercetin within 24 hours

Primary Outcome Measures :
  1. antioxidant status after 24 hours [ Time Frame: 24 hours ]
  2. inflammatory status after 24 hours [ Time Frame: 24 hours ]

Secondary Outcome Measures :
  1. plasma quercetin concentration after 24 hours [ Time Frame: 24 hours ]
  2. plasma malondialdehyde (MDA) levels after 24 hours [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • clinical diagnosis of sarcoidosis with emphasize on pulmonary sarcoidosis
  • no smoking
  • no treatment

Exclusion Criteria:

  • clinical diagnosis (and treatment) of other diseases
  • symptoms of sarcoidosis in other organs besides the lung
  • use of food supplements or vitamins

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00402623

Layout table for location information
Maastricht University
Maastricht, Netherlands, 6200 MD
Sponsors and Collaborators
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Layout table for investigator information
Study Chair: Aalt Bast, PhD Maastricht University
Principal Investigator: Agnes W Boots, PhD Maastricht University
Study Director: Guido R Haenen, PhD Maastricht University
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Dr. A.W. Boots, Maastricht University Identifier: NCT00402623    
Other Study ID Numbers: MEC 05.142.5
First Posted: November 22, 2006    Key Record Dates
Last Update Posted: February 24, 2017
Last Verified: February 2008
Keywords provided by Maastricht University Medical Center:
oxidative stress
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoproliferative Disorders
Lymphatic Diseases
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs